The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

Victoza sales declined 22% during the reported ... primarily driven by increased sales volumes of GLP-1-based treatments for obesity and diabetes care. Per NVO, the impact of intensifying ...

In one of the most comprehensive analyses to date, researchers examined health records of nearly 216,000 veterans to map out the full range of effects associated with GLP-1 receptor agonists (GLP ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people ... Liraglutide is on the market as Victoza for diabetes and Saxenda for obesity.

Older GLP-1 medications like Victoza, Trulicity and even Ozempic possess one underlying mechanism. As "GLP-1 receptor agonists," they mimic a naturally occurring hormone, GLP-1, released in the ...

ST. LOUIS — A new study reveals that popular diabetes and weight loss medications like Ozempic and Wegovy may offer unexpected health benefits, from reducing addiction risk to protecting against ...